Abstract: A polymer-protein core-shell nanoparticle is generally provided. In one embodiment, the polymer-protein core-shell nanoparticle includes a pyridinyl group grafted polymer assembled with a protein or a glycoprotein based antigen to form a core-shell particle. A method is also generally provided for treating an infected organism. In one embodiment, the method includes administering the polymer-protein core-shell nanoparticle to the infected organism.
Abstract: A porous material of a medical implant material, the material body of which is a hierarchical porous material with multilevel pore cavities graded according a pore size of the material. The permeability of the hierarchical porous material is more than 0.5×10?9 m2. The hierarchical porous material can fully ensure blood flow, achieve transmission of adequate nutrients and growth factors, migration of cells, and remove cell fragments and stimulate tissue growth, and has various functions, thus fully satisfying the requirements of human tissue regeneration.
Abstract: The invention relates to the use of sphingosine based compounds, in particular phytosphingosine compounds, in the protection of hydroxyapatite containing materials such as teeth and bone. Such compounds are especially useful in the treatment and prevention of dental caries, dental erosion, dentine hypersensitivity and tartar (dental calculus) formation. Methods and devices are also provided for preventing biofilm formation using sphingosine based compounds. Compositions comprising sphingosine based compounds are also provided.
Type:
Grant
Filed:
April 26, 2013
Date of Patent:
March 15, 2022
Assignee:
STICHTING VU
Inventors:
Floris Jacob Bikker, Engelmundus Cornelis Ignatius Veerman, Marianne Valentijn-Benz, Willem Van 'T Hof
Abstract: Disclosed are melanin compositions and devices, and methods of use thereof, to protect internal tissues and organs from radiation damage and to prevent or alleviate negative side effects associated with radiation exposure.
Abstract: The present invention relates to the field of nanotechnology, in particular, to the production of biodegradable polymeric nanoparticles. The present invention provides a biodegradable polymeric nanoparticle made up of a block copolymer and a process for producing the same. The nanoparticles are produced without the use of any emulsifiers and have a size ranging from 30-120 nm. The methods of controlling the drug loading capacity are disclosed along with the process of producing entity-loaded nanoparticles. Compositions comprising the nanoparticles and their use in therapeutics, diagnostics and theranostics are also disclosed.
Abstract: The present disclosure provides polymer conjugates comprising a polymer and an agent, the agent linked to the polymer via a linking group containing a hydrolyzable moiety.
Abstract: A novel multi-arm polyethylene glycol (PEG) (I) and preparation method thereof. Active derivatives (II) based on the multi-arm PEG. Gels formed of the active derivatives. Drug conjugates formed of the active derivatives and drug molecules and uses thereof in medical preparation. The multi-arm PEG is formed by polymerizing ethylene oxide with pentaerythritol oligomers as initiator, wherein PEG is the same or different and is a —(CH2CH2O)m-, the average value of m is an integer of 3-1000, l is an integer more than or equal to 2. An 8-arm PEG is preferred, wherein l is equal to 3. The active derivatives (II) comprise link groups X attached to PEG and active end groups F attached to X.
Abstract: To provide a medical device including a substrate and a hydrophilic polymer layer formed on at least a part of the substrate, which satisfies the following conditions (a) to (d): (a) a polymer constituting the hydrophilic polymer layer is a hydrophilic polymer having an acidic group; (b) the hydrophilic polymer layer has a thickness of 1 nm or more and less than 100 nm; (c) a number ratio of basic group/acidic group of the hydrophilic polymer layer is 0.2 or less; and (d) a liquid film retention time at 40 minutes after ultrasonic cleaning in a phosphate buffer solution is 15 seconds or more. The present invention provides a medical device in which a surface of a substrate is hydrophilized, and a method for manufacturing same by a simple method.
Abstract: A bioadhesive includes a crosslinked biodegradable hydrogel that includes a plurality of oxidized, acrylated or methacrylated, natural polymer.
Abstract: The invention provides novel solid pharmaceutical dosage forms for oral administration, after being constituted in water. The solid dosage forms comprise a therapeutically effective amount of valganciclovir hydrochloride and a non-hygroscopic organic acid present in an amount sufficient to stabilize the valganciclovir hydrochloride in a predetermined amount of water. The present invention also provides novel liquid pharmaceutical dosage forms for oral administration after constituting the solid pharmaceutical dosage form with water. A non-hygroscopic bulking agent may optionally be included in the above dosage form. These novel pharmaceutical dosage forms are useful in the treatment or control of viruses such as herpes simplex virus and cytomegalovirus. The present invention also provides a method for treating these diseases employing the solid and liquid pharmaceutical dosage forms and a method for preparing these pharmaceutical dosage forms.
Type:
Grant
Filed:
December 19, 2018
Date of Patent:
November 30, 2021
Assignee:
Hoffmann-La Roche Inc.
Inventors:
Maria Oksana Bachynsky, Martin Howard Infeld, Navnit Hargovindas Shah
Abstract: The invention generally relates to compositions comprising degradable polymers and methods of making degradable polymers. Specifically, the disclosed degradable polymers comprise a biodegradable polymer backbone, a nitric oxide linker moiety, and a nitric oxide molecule. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
Type:
Grant
Filed:
October 5, 2017
Date of Patent:
November 30, 2021
Assignee:
The University of North Carolina at Chapel Hill
Abstract: A pharmaceutical formulation of testosterone undecanoate is provided. Methods of treating a testosterone deficiency or its symptoms with the inventive formulations are also provided.
Type:
Grant
Filed:
October 17, 2019
Date of Patent:
November 23, 2021
Assignee:
Clarus Therapeutics, Inc.
Inventors:
Robert E. Dudley, Panayiotis P. Constantinides
Abstract: A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided.
Type:
Grant
Filed:
November 15, 2017
Date of Patent:
November 23, 2021
Assignee:
Clarus Therapeutics, Inc.
Inventors:
Robert E. Dudley, Panayiotis P. Constantinides
Abstract: The present invention relates to macromolecular transition metal complexes, characterized by having the general formula (I), to the process for their preparation, and to bidentate and monodentate macroligands. The invention also refers to pharmaceutical compositions and medicaments containing said macromolecular transition metal complexes, and to the use of said pharmaceutical compositions, medicaments and macromolecular transition metal complexes for cancer therapy and/or cancer prevention, as antitumor agent in solid tumors, liquid tumors and/or metastases and/or as radiosensitizer agents.
Type:
Grant
Filed:
December 7, 2015
Date of Patent:
November 9, 2021
Assignee:
FACULDADE DE CIÉNCIAS DA UNIVERSIDADE DE LISBOA
Inventors:
Maria Helena Anselmo Viegas Garcia, Andreia Marques Valente, Tânia Sofia Ferreira Morais, Ana Isabel Antunes Tomaz Diniz
Abstract: Described is a composition comprising (a) a population of particles of an aripiprazole prodrug having a volume based particle size (Dv50) of less than 1000 nm and (b) at least one surface stabilizer comprising an adsorbed component which is adsorbed on the surface of the aripiprazole prodrug particles and a free component available for solubilisation of the aripiprazole prodrug. The surface stabilizer to prodrug ratio provides the optimal quantity of free surface stabilizer for the purposes of producing a lead-in formulation. Also described are methods of treatment using the aforementioned composition.
Type:
Grant
Filed:
June 17, 2020
Date of Patent:
October 26, 2021
Assignee:
ALKERMES PHARMA IRELAND LIMITED
Inventors:
Philip Cresswell, Magali Hickey, Kristopher Perkin, Greg Smith, Elaine Liversidge, Brian Steinberg, David Manser, Tarek Zeidan
Abstract: A composition comprises phenolic polymer particles and a surfactant, on the phenolic polymer particles. The composition is lipophilic. A dispersion comprises the phenolic polymer particles, the surfactant, and a carrier vehicle. The carrier vehicle may be a cosmetically-acceptable fluid or a wax that is lipophilic.
Type:
Grant
Filed:
September 13, 2019
Date of Patent:
October 26, 2021
Assignee:
Nanophase Technologies Corporation
Inventors:
Harry W. Sarkas, Christopher C. Boffa, Kevin Cureton
Abstract: Mixed ligand phosphinogold(I) complexes as anticancer agents. The gold(I) ion of the complexes is coordinated to a phosphine and a dithiocarbamate or halogen ligand. Also described are a pharmaceutical composition incorporating the phosphinogold(I) complex, a method of synthesizing the phosphinogold(I) complex, and a method of treating cancer. The phosphinogold(I) complexes exhibit potent cytotoxicity against lung, cervical, and liver cancer cells.
Type:
Grant
Filed:
March 10, 2020
Date of Patent:
October 12, 2021
Assignees:
King Fahd University of Petroleum and Minerals, King Saud University
Inventors:
Anvarhusein A. Isab, Adam Ahmed Abdullah Sulaiman, Ali Alhoshani
Abstract: The invention relates to a cosmetic composition, especially a hair composition, and to a method for the cosmetic treatment of keratin materials, especially of the hair, employing compounds of formula: in which Z represents (i) a hydrogen atom, (ii) a linear or branched C1 to C32 (saturated) alkyl radical; (iii) a linear or branched C2 to C32 (unsaturated) alkene radical, comprising one or two C?C double bonds; (iv) an aryl-substituted alkyl radical; said radicals being optionally substituted and/or interrupted.
Type:
Grant
Filed:
May 15, 2018
Date of Patent:
October 12, 2021
Assignee:
L'OREAL
Inventors:
Anne-Claude Dublanchet, Christian Blaise, Abel Messavussu
Abstract: Pharmaceutical compositions and dosage forms of (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate and/or methyl 4-morpholin-4-ylbutyl (2E)but-2-ene-1,4-dioate, containing low levels of certain impurities are disclosed.
Type:
Grant
Filed:
May 15, 2018
Date of Patent:
October 5, 2021
Assignee:
Arbor Pharmaceuticals, LLC
Inventors:
Suresh Kumar Manthati, Sami Karaborni, Wei Chen
Abstract: The invention relates to a drug delivery device adapted for carrying and delivering both hydrophilic and lipophilic drug molecules. The drug delivery device includes a porous body for adsorption of drug molecules, the body including a plurality of microspheres, and a hydrogel forming cross-links connecting the plurality of microspheres.